Otsuka America Pharmaceutical US
Manufacturing · New Jersey, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
508 Carnegie Ctr, Princeton, New Jersey,...Phone Number
(609) 524-6788Website
www.otsuka-us.comRevenue
$675.1 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
2
1
About Otsuka America Pharmaceutical US
Otsuka America Pharmaceutical is a researcher, developer, manufactures, and marketer of pharmaceutical products. The company offers tablets, injections, conditioning agents, and medical devices.Explore more
Otsuka America Pharmaceutical US Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Otsuka America Pharmaceutical US your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Otsuka America Pharmaceutical US had a recent Job posting/layoffs
Check if Otsuka America Pharmaceutical US has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Otsuka America Pharmaceutical US has new funding data
Product Launch: Get notified when Otsuka America Pharmaceutical US launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Otsuka America Pharmaceutical US recently announced quarterly report
Otsuka America Pharmaceutical US, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Otsuka America Pharmaceutical US
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Otsuka America Pharmaceutical US is spiking on competitors!
Recommended Actions
Find VP level buyers at Otsuka America Pharmaceutical US
Find more new buyers
Compare Similar Companies to Otsuka America Pharmaceutical US
Compare insights from companies similar to Otsuka America Pharmaceutical US, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Otsuka America Pharmaceutical US is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Otsuka America Pharmaceutical US is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Otsuka America Pharmaceutical US.
Otsuka America Pharmaceutical US Tech Stack
A closer look at the technologies used by Otsuka America Pharmaceutical US
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Left Company
Executive Move
Executive Moves, Left Company
Otsuka America Pharmaceutical US News & Media
Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn™, the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) announce today the commercial launch of Rejoyn™. Rejoyn was cleared by the U.S. Food and Drug Administration (FDA) in March 2024 and is the first-and-only prescription digital therapeutic for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant meAbilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months[1.] Windsor, United Kingdom/Valby, Denmark, 27 March, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Abilify Maintena[®] 960 mg (aripiprazole) as a once-every-two-months long-acting injectable (LAI) formulation for the maintenance treatment of schizophrenia in adult patients stabilisedAripiprazole once-every-two-months long-acting injectable recommended for approval in the EU by the CHMP for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole
Subject to final approval by the European Commission, the drug will be the first once-every-two-months long-acting injectable (LAI) antipsychotic licensed in the EU for adult patients with schizophrenia stabilised with aripiprazole. Windsor, United Kingdom/Valby, Denmark, 29 January, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinioOlympic Gold Medalist Missy Franklin Collaborates with Otsuka to Raise Awareness of Kidney Disease and Encourage Family Health History Conversations
Former Professional Swimmer Discusses Her Family's Journey with Autosomal Polycystic Kidney Disease PRINCETON, N.J., Nov. 1, 2023 /PRNewswire/ -- This Family Health History Month, five-time Olympic gold medalist Missy Franklin is teaming up with Otsuka America Pharmaceutical, Inc....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Otsuka America Pharmaceutical US
Sign Up For FreeTo access detailed company insights
Otsuka America Pharmaceutical is a researcher, developer, manufactures, and marketer of pharmaceutical products. The company offers tablets, injections, conditioning agents, and medical devices.... Read More
